Jason Butler
Stock Analyst at JMP Securities
(4.42)
# 299
Out of 4,944 analysts
139
Total ratings
46.9%
Success rate
22.1%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $33 → $95 | $69.89 | +35.93% | 4 | Jul 23, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $15.62 | +79.26% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $25.13 | +47.23% | 14 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $12.56 | +210.51% | 5 | Jun 24, 2025 | |
| PGEN Precigen | Reiterates: Market Outperform | $6 | $1.91 | +214.14% | 11 | Jun 12, 2025 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $78 → $29 | $8.05 | +260.25% | 10 | May 27, 2025 | |
| TTD The Trade Desk | Maintains: Market Outperform | $115 → $100 | $54.36 | +83.96% | 1 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Market Outperform | $42 → $38 | $18.86 | +101.54% | 8 | May 7, 2025 | |
| CYTK Cytokinetics | Reiterates: Market Outperform | $78 | $36.88 | +111.50% | 16 | Apr 10, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Market Outperform | $17 → $18 | $9.43 | +90.88% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $1.94 | +106.19% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $646.60 | +8.41% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $33 | $10.83 | +204.85% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $6.47 | +39.10% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $72 → $73 | $65.13 | +12.08% | 13 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $4.01 | +124.44% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.39 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $12.08 | +57.28% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $1.09 | +1,918.35% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.81 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $7.18 | +584,858.22% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $7.60 | +1,426.32% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $3.37 | +167.06% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.86 | - | 1 | Dec 2, 2020 |
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Market Outperform
Price Target: $33 → $95
Current: $69.89
Upside: +35.93%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $15.62
Upside: +79.26%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $25.13
Upside: +47.23%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $12.56
Upside: +210.51%
Precigen
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $1.91
Upside: +214.14%
Prothena Corporation
May 27, 2025
Maintains: Market Outperform
Price Target: $78 → $29
Current: $8.05
Upside: +260.25%
The Trade Desk
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $54.36
Upside: +83.96%
Viridian Therapeutics
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $18.86
Upside: +101.54%
Cytokinetics
Apr 10, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $36.88
Upside: +111.50%
Zevra Therapeutics
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $9.43
Upside: +90.88%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $1.94
Upside: +106.19%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $646.60
Upside: +8.41%
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $10.83
Upside: +204.85%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $6.47
Upside: +39.10%
Nov 1, 2024
Maintains: Market Outperform
Price Target: $72 → $73
Current: $65.13
Upside: +12.08%
Oct 8, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $4.01
Upside: +124.44%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.39
Upside: -
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $12.08
Upside: +57.28%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $1.09
Upside: +1,918.35%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.81
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $7.18
Upside: +584,858.22%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $7.60
Upside: +1,426.32%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $3.37
Upside: +167.06%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $0.86
Upside: -